Lancet
-
Randomized Controlled Trial Clinical Trial
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial.
Prostate carcinoma is linked to osteoblastic metastasis. We therefore investigated the value of bone-targeted consolidation therapy in selected patients with advanced androgen-independent carcinoma of the prostate. ⋯ Bone-targeted consolidation therapy consisting of one dose of Sr-89 plus doxorubicin once a week for 6 weeks, when given to patients with stable or responding advanced androgen-independent carcinoma of the prostate after induction chemotherapy, improved overall survival.